Clinical Trial

Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)

Study acronym: VISIONAIRE
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
VISIONAIRE (Vitamin K AntagonISt, Factor Xa Inhibitor Or Nothing In Atrial Fibrillation And DIalytic End-stage Renal DiseasE) trial will be a prospective randomized open-label with blinded endpoint adjudication trial including 1500 patients with atrial fibrillation or atrial flutter and advanced chronic kidney disease
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-03; most recent amendment 2025-02-19.
Status change: Not Yet Recruiting → Recruiting 2025-02-19
Trial Details
NCT Number NCT06402851
Lead Sponsor Hospital Sirio-Libanes
Collaborators: Daiichi Sankyo
Conditions Atrium; Fibrillation, Chronic Kidney Diseases
Enrollment 1,500 participants
Start Date 2024-12-18
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-02-21